Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
The Real Full Monty Strips Down
Inspired by the beloved, award-winning 1997 film, The Real Full Monty is an all-new two-hour special in which a daring group of male celebrities will volunteer to bare all to raise awareness for prostate, testicular and colorectal cancer testing and research.
Trump administration offers challenges, opportunities in 2025 and beyond
The Colorectal Cancer Alliance outlines 2025 advocacy priorities under the Trump administration and Republican-controlled Congress, including funding research and improving care access.
Alliance Celebrates 25 Years & Honors Notable Partners at the National Blue Hope Bash
The Colorectal Cancer Alliance’s national Blue Hope Bash, held November 2 at the National Building Museum in Washington, D.C., raised nearly $2 million to support lifesaving work.